Skip to main content
. 2020 Nov 10;11(4):935–948. doi: 10.1016/j.jcmgh.2020.11.003

Figure 5.

Figure 5

EK1 but not famotidine inhibit infection of PSC-HIOs with SARS-CoV-2. (A) Caco-2 cells were infected with SARS-CoV-2 and treated with famotidine at indicated concentrations. Two days later, infection was quantified by an enzyme-based immunodetection assay against viral S protein. Values shown represent mean values derived from triplicate infections ± SEM from one representative experiment. Experiment was performed 2 times. (B) Effect of famotidine on metabolic activity of Caco-2 cells was assessed by CellTiter-Glo assay. Values shown represent mean values derived from triplicates ± SEM from one representative experiment. (C–E) PSC-HIOs were infected with SARS-CoV-2 and treated with (C) famotidine or (E) EK1. Two days later, infection was analyzed by staining for viral S protein (red). Ecad (green) was additionally stained to visualize cells. Nuclei are stained with DAPI in blue. Scale bar = 50 μM. (D) SARS-CoV-2 N was quantified in cellular RNA isolates of PSC-HIOs treated with either distinct dosages of famotidine and normalized to GAPDH RNA (n = 1, values represent means ± SEM of technical duplicates). (F) Images from panels C and E were quantified according to the presence of viral S protein compared with total cell number (n = 2–3 independent experiments, at least 3 organoids counted per experiment; values represent mean ± SEM).